Table 1.
Patient characteristics, stage and tumor location
| Lynch syndrome (n=37) | MLH1-hm (n=106) | p-value | |
|---|---|---|---|
| Age (median; Q1,Q3) | 47 (35, 58) | 70.5 (63,80) | p< 0.0001 |
| Sex | |||
| Male | 22 (59.5%) | 45 (42.5%) | p=0.074 |
| Female | 15 (40.5%) | 61 (57.5%) | |
| Race | |||
| Caucasian | 33 (89.2%) | 88 (89.8%) | p=0.775 |
| AA | 3 (8.1%) | 9 (9.2%) | |
| Hispanic | 1 (2.7%) | 1 (1.0%) | |
| Stage | |||
| I | 4 (10.8%) | 15 (14.2%) | p=0.022 |
| II | 10 (27.0%) | 48 (45.3%) | |
| III | 17 (46.0%) | 28 (26.4%) | |
| IV | 3 (8.1%) | 14 (13.2%) | |
| Stage I–III (unknown) | 3 (8.1%) | 1 (0.9%) | |
| Location | |||
| Right | 27 (73.0%) | 87 (82.9%) | p=0.457 |
| Left | 7 (18.9%) | 11 (10.5%) | |
| Rectum | 3 (8.1%) | 7 (6.7%) | |
| Synchronous | 4 (10.8%) | 6 (5.7%) | p=0.459 |
| Metachronous | 7 (18.9%) | 4 (3.8%) | p=0.009 |
| Received adjuvant chemotherapy | |||
| Stage II | 3 (30%) | 4 (8.3%) | p=0.058 |
| Stage III | 10 (59%) | 11 (39%) | P=0.091 |
| Recurrence (%) | 9 (24.3%) | 12 (11.3%) | p=0.040 |
| Other cancer diagnosis (%) | 13 (34.2%) | 27 (25.5%) | p=0.301 |
| Follow-up time (months) | |||
| (median; Q1,Q3) | 30.0 (16, 117) | 25 (5, 54) | p=0.02 |
| CEA (n, median; Q1, Q3) | 1.2 (0.7, 2.6) | 1.9 (1.0, 5.6) | P=0.070 |
AA = African-American; Q = quartiles; Statistical significance was evaluated by Chi-square for categorical variables and t-test for continuous variables. Significance was set at p<0.05.